Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma.
Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Delta(9)-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma.
复制标题
DOI：
10.1007/s00216-010-3599-6
复制
发表时间：
2010-05
影响因子：
4.3
通讯作者：
Huestis, Marilyn A.
中科院分区：
文献类型：
--
作者：
Karschner, Erin L.;Barnes, Allan J.;Lowe, Ross H.;Scheidweiler, Karl B.;Huestis, Marilyn A.
A sensitive analytical method for simultaneous quantification of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH) in plasma is presented for monitoring cannabinoid pharmacotherapy and illicit cannabis use. Analytes were extracted from 1 mL plasma by solid phase extraction, derivatized with N, O,-bis(trimethylsilyl) trifluoroacetamide with 1% trimethylchlorosilane, and analyzed by two-dimensional gas chromatography mass spectrometry (2D-GCMS) with cryofocusing. The lower calibration curve was linear from 0.25–25 ng/mL for CBD and THC, 0.125–25 ng/mL for 11-OH-THC and 0.25–50 ng/mL for THCCOOH. A second higher linear range from 5–100 ng/mL, achieved through modification of injection parameters, was validated for THC, 11-OH-THC and THCCOOH and was only implemented if concentrations exceeded the lower curve upper limit of linearity. This procedure prevented laborious re-extraction by allowing the same specimen to be re-injected for quantification on the high calibration curve. Intra- and inter-assay imprecision, determined at four quality control concentrations, were <7.8% CV. Analytical bias was within ±9.2% of target and extraction efficiencies were >72.9% for all analytes. Analytes were stable when stored at 22°C for 16h, 4°C for 48h, after three freeze-thaw cycles at −20°C and when stored on the autosampler for 48h. This sensitive and specific 2D-GCMS assay provides a new means of simultaneously quantifying CBD, THC and metabolite biomarkers in clinical medicine, forensic toxicology, workplace drug testing, and driving under the influence of drugs programs.
登录
查看更多内容
影响因子：
2.5
作者：
Moore, C;Rana, S;Prest, H
通讯作者：
Prest, H
影响因子：
2.5
作者：
Moore, Christine;Coulter, Cynthia;Soares, James
通讯作者：
Soares, James
DOI：
10.1300/j175v03n04_02
发表时间：
2003-01-01
期刊：
Journal of Cannabis Therapeutics
影响因子：
--
作者：
Guy, G. W.;Robson, P. J.
通讯作者：
Robson, P. J.
影响因子：
2.5
作者：
Nadulski, T;Sporkert, F;Pragst, F
通讯作者：
Pragst, F
DOI：
10.1016/j.jchromb.2003.09.022
发表时间：
2003-12-05
影响因子：
3
作者：
Gustafson, RA;Moolchan, ET;Huestis, MA
通讯作者：
Huestis, MA